Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. addition

ADDITION

Arthritis Differential DIagnostic validaTION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADDITION project word cloud

Explore the words cloud of the ADDITION project. It provides you a very rough idea of what is the project "ADDITION" about.

web    biopsy    economic    synovial    consists    useless    predict    feasibility    acr    arthritis    few    group    computing    ing    diseases    line    signature    cohort    earlier    unsatisfactory    turnover    rheumakit    complemented    techniques    functional    efficacy    inflammation    limited    40    ua    patients    pcr    infrastructure    socio    joints    prospective    vs    cloud    strategies    validated    marked    unjustified    1000    tool    clinically    distinction    trancriptomic    osteoarthritis    leads    ra    patient    methotrexate    first    collection    central    annual    huge    criterion    140m    2014    differential    impacts    lab    seronegative    diagnosed    health    treatment    newly    clinical    transportation    inappropriate    larger    500    mtx    logistics    progression    clinicians    rheumatoid    90    probabilities    describes    kit    ce    ea    genes    undifferentiated    eular2010    therapeutic    spondylarthropaties    solution    280m    subclass    validate    diagnostic    ineffective    expenses    serious    provides    adequacy    accuracy    procedure    involve    treatments    incidence    mistake    market    suffering   

Project "ADDITION" data sheet

The following table provides information about the project.

Coordinator		 DNALYTICS 

Organization address
address: CHEMIN DU CYCLOTRON 6
city: OTTIGNIES LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Project website http://www.dnalytics.com. The RheumaKit online platform
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DNALYTICS BE (OTTIGNIES LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Arthritis, a group of diseases involving inflammation of joints with huge health and socio-economic impacts. Early Arthritis (EA) describes newly diagnosed arthritis (incidence 2/1000). An improved arthritis management requires to enhance the EA differential diagnostic efficacy and the adequacy of the therapeutic strategies. The earlier arthritis is addressed, the more likely its progression will be limited. A mistake in differential diagnostic leads to inappropriate treatments, resulting in useless expenses and serious side effects, unjustified. Current diagnostic techniques are unsatisfactory and the most used first line treatment, Methotrexate (MTX), is ineffective in about 40% of the patients. RheumaKit is a solution for clinicians for the early differential diagnostic of patients suffering from undifferentiated arthritis (UA, a subclass of EA). RheumaKit is based on a trancriptomic signature of about 100 genes complemented by 3 clinical factors. It provides a 90% accuracy for the Rheumatoid Arthritis (RA) vs non-RA distinction, far above the ACR/EULAR2010 criterion on the same patients. It also provides probabilities for Osteoarthritis and Seronegative Spondylarthropaties. The solution consists of a synovial biopsy collection and transportation kit (CE-marked May 2014), a central lab PCR procedure, and a web application computing the effective diagnostic on a cloud-computing infrastructure. Functional, technical, logistics aspects of RheumaKit have been validated. ADDITION aims at clinically validate on a larger patient cohort the existing RheumaKit signature for the differential diagnostic of most EA patients and validate the use of the existing RheumaKit signature as a tool to predict MTX response. ADDITION phase 2 will involve a prospective study on 500 to 1000 EA patients. The main phase 1 objectives are a feasibility study of the clinical and market aspects of ADDITION. The expected annual turnover is above 140M€-280M€ in EU within a few years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDITION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDITION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More